Focus: CryoPort Systems is a newly founded (2024) biotechnology company specializing in temperature-controlled supply chain solutions for advanced therapies across multiple therapeutic areas. The company operates from Brentwood, Tennessee and is actively scaling operations across supply chain, engineering, and regulatory infrastructure.
Profile data last refreshed 17h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
7 added, 5 removed. Backfill posture.
CryoPort Systems is a high-risk, high-reward early-stage bet for supply chain or engineering professionals seeking founder-level equity upside, but unsuitable for those seeking financial stability, research depth, or clinical trial exposure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CryoPort Systems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CryoPort Systems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company